These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38824414)

  • 81. A non-linear optimisation method to extract summary statistics from Kaplan-Meier survival plots using the published P value.
    Irvine AF; Waise S; Green EW; Stuart B
    BMC Med Res Methodol; 2020 Oct; 20(1):269. PubMed ID: 33126853
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors.
    Saleh RR; Meti N; Ribnikar D; Goldvaser H; Ocana A; Templeton AJ; Seruga B; Amir E
    Cancer Med; 2020 Nov; 9(21):7888-7895. PubMed ID: 32886422
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
    Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
    Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Interpretation of clinical endpoints in trials of acute myeloid leukemia.
    Medeiros BC
    Leuk Res; 2018 May; 68():32-39. PubMed ID: 29524739
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 86. CHALLENGES AND METHODOLOGIES IN USING PROGRESSION FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN ONCOLOGY.
    Hernandez-Villafuerte K; Fischer A; Latimer N
    Int J Technol Assess Health Care; 2018 Jan; 34(3):300-316. PubMed ID: 29987997
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The Trials (and Tribulations) of Complementary and Alternative Medicine in Oncology.
    Ludmir EB; Jethanandani A; Mainwaring W; Miller AB; Lin TA; Espinoza AF; Verma V; VanderWalde NA; Grossberg AJ; Guadagnolo BA; Koong AC; Jagsi R; Thomas CR; Fuller CD
    J Natl Cancer Inst; 2019 Dec; 111(12):1358-1360. PubMed ID: 31165160
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
    Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
    Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Drawing Guideline for
    Kim J
    J Korean Med Sci; 2019 Mar; 34(8):e35. PubMed ID: 30833878
    [TBL] [Abstract][Full Text] [Related]  

  • 90. HIS-based Kaplan-Meier plots--a single source approach for documenting and reusing routine survival information.
    Breil B; Semjonow A; Müller-Tidow C; Fritz F; Dugas M
    BMC Med Inform Decis Mak; 2011 Feb; 11():11. PubMed ID: 21324182
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
    Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
    J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Evaluation of the quality of the reporting of phase II clinical trials in oncology: A systematic review.
    Rivoirard R; Langrand-Escure J; Oriol M; Tinquaut F; Chauvin F; Rancoule C; Magné N; Bourmaud A
    Crit Rev Oncol Hematol; 2018 May; 125():78-83. PubMed ID: 29650280
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial.
    Markman M
    Curr Oncol Rep; 2004 Nov; 6(6):421-2. PubMed ID: 15485610
    [No Abstract]   [Full Text] [Related]  

  • 95. Comparison of futility monitoring guidelines using completed phase III oncology trials.
    Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
    Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A).
    Niimi M; Yamamoto S; Fukuda H; Ishizuka N; Akaza H
    Jpn J Clin Oncol; 2002 Jan; 32(1):19-26. PubMed ID: 11932358
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Stakeholder perspectives on the use of positron emission tomography in phase III oncology trials in the UK.
    Rojas-Anaya H; Skogen K; Miles KA
    Nucl Med Commun; 2012 Jun; 33(6):626-32. PubMed ID: 22543952
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.
    Rosas SR; Schouten JT; Dixon D; Varghese S; Cope MT; Marci J; Kagan JM
    Clin Trials; 2014 Oct; 11(5):553-9. PubMed ID: 24980279
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis.
    Veas Rodríguez J; Prieto A; Vilaprinyo E; Bonet M; Diez M; Salud A; Montal R
    Crit Rev Oncol Hematol; 2024 Sep; 201():104416. PubMed ID: 38871262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.